{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_001126112.3:c.5981G>A",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "A",
            "position": "5981"
          },
          "Protein Change": {
            "ref": "I",
            "alt": "T",
            "position": "2020"
          },
          "Description in input context": "I2020T"
        },
        {
          "HGVS": "NM_001126112.3:c.5980G>A",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "A",
            "position": "5980"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "1993"
          },
          "Description in input context": "G2013S"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005238"
  },
  "Experiment Method": [
    {
      "Assay Method": "Binding assay",
      "Material used": {
        "Material Source": "Recombinant LRRK2 protein",
        "Material Name": "LRRK2",
        "Description": "Binding assays were performed to compare ATP affinity of LRRK2 mutants to wild-type."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.5981G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Altered ATP binding affinity",
          "Result Description": "I2020T exhibited 2.3-fold reduced ATP affinity compared to wild-type."
        },
        {
          "Variant": "NM_001126112.3:c.5980G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Altered ATP binding affinity",
          "Result Description": "G2013S exhibited 1.8-fold reduced ATP affinity compared to wild-type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the literature."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the literature."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 served as the positive control."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly described in the literature."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D.",
        "Description": "Not explicitly described in the literature."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "ATP affinity ratio within 1.2-fold of wild-type",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "ATP affinity ratio ≥ 1.5-fold deviation from wild-type",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "In vitro kinase activity assay",
      "Material used": {
        "Material Source": "Recombinant LRRK2 protein",
        "Material Name": "LRRK2",
        "Description": "Kinase activity assays were performed to evaluate inhibitor sensitivity."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.5981G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased inhibitor resistance",
          "Result Description": "I2020T showed 3.1-fold resistance to ATP-competitive inhibitors."
        },
        {
          "Variant": "NM_001126112.3:c.5980G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased inhibitor sensitivity",
          "Result Description": "G2013S showed 1.6-fold reduced inhibitor resistance."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly described in the literature."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly described in the literature."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 served as the positive control."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly described in the literature."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D.",
        "Description": "Not explicitly described in the literature."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Kinase activity within 1.5-fold of wild-type",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Kinase activity ≥ 2-fold deviation from wild-type",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}